$84.00 – $154.00Price range: $84.00 through $154.00
With extensive experience in compound synthesis, we can provide rapid custom synthesis services for this product according to your research needs.
Questions
Tirzepatide Common Questions
What’s pIC50?
pIC50 is the negative log of the IC50 value when converted to molar.That is, pIC50=-log(IC50).
What’s Kd?
Dissociation consent (Kd) reflects the affinity of a compound for its target. In some cases, it can be equivalent to Ki.
Description
5-Amino-1-methylquinolinium (5-Amino-1MQ) is a small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT). It is commonly used in metabolic research to study pathways related to energy expenditure, adipogenesis, and methylation balance. By inhibiting NNMT activity, 5-Amino-1MQ modulates NAD⁺ metabolism and cellular methyl donor utilization, making it a useful tool compound in obesity and metabolic disorder research.
Targets & IC50
Targets: Nicotinamide N-methyltransferase (NNMT)
IC50: ~1–5 μM (reported range, assay-dependent)
In vitro
METHODS: 3T3-L1 preadipocytes and human adipocyte cell models were treated with 5-Amino-1MQ (0–20 μM) for 24–96 hours. NNMT activity, intracellular NAD⁺ levels, and adipogenic differentiation were assessed using enzymatic assays, lipid staining, and Western blot analysis of metabolic markers.
RESULTS: 5-Amino-1MQ inhibits NNMT activity in a concentration-dependent manner, leading to increased intracellular NAD⁺ levels and altered methylation balance. It reduces adipocyte differentiation and lipid accumulation, while modulating metabolic signaling pathways associated with energy expenditure. No significant cytotoxicity is observed at commonly used experimental concentrations. [1]
Synonyms
5-Amino-1MQ
Molecular Weight
~174.22
Formula
C₁₀H₁₀N₂⁺
Cas No.
Not universally standardized / varies by salt form
Smiles
Cn1ccc2cc(N)ccc2c1
Relative Density.
no data available
Sequence
Not applicable (small molecule, non-peptide)
Sequence Short
no data available
Storage
Formula
No account yet?
Create an AccountContact Us